LB-102

Schizophrenia

Manufacturer: LB Pharmaceuticals Inc
Regulatory submission: Not announced
Launch: Not announced
Last updated: October 8, 2026

Section

Product information and disease description Place of product in therapy

Approaches to treatment

122 evidence topics · 74 sources

Current treatment options and standard of care72 evidence topics · 48 sources
Place in treatment, anticipated use, and care setting13 evidence topics · 14 sources
Heterogeneity of treatment effect12 evidence topics · 12 sources
Care management intervention strategies12 evidence topics · 15 sources
Other product development or post-marketing obligations required by the FDA2 evidence topics · 2 sources
Expected outcomes of therapy11 evidence topics · 14 sources

Ongoing post-approval monitoring

Post-approval monitoring requirements

Not applicable.